ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
7.480 USD   -0.93%
05/19Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
GL
05/19Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
AQ
05/10TRANSCRIPT : Allogene Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 08:00 AM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Allogene Therapeutics Enters Into Cancer Therapy Collaboration With Antion Biosciences

01/11/2022 | 10:11am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ALLOGENE THERAPEUTICS, INC. -0.93% 7.48 Delayed Quote.-49.87%
ON SEMICONDUCTOR CORPORATION 0.70% 56.46 Delayed Quote.-16.87%
All news about ALLOGENE THERAPEUTICS, INC.
05/19Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Imp..
GL
05/19Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Imp..
AQ
05/10TRANSCRIPT : Allogene Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Confe..
CI
05/10Allogene Therapeutics Named 2022 Bay Area 'Best Place to Work' by San Francisco Busines..
AQ
05/09Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Franc..
GL
05/05Raymond James Adjusts Allogene Therapeutics' Price Target to $13 from $36, Keeps Outper..
MT
05/04TRANSCRIPT : Allogene Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04ALLOGENE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
05/04ALLOGENE THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/04ALLOGENE THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
More news
Analyst Recommendations on ALLOGENE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 0,12 M - -
Net income 2022 -366 M - -
Net cash 2022 430 M - -
P/E ratio 2022 -2,91x
Yield 2022 -
Capitalization 1 074 M 1 074 M -
EV / Sales 2022 5 455x
EV / Sales 2023 133x
Nbr of Employees 334
Free-Float 55,9%
Chart ALLOGENE THERAPEUTICS, INC.
Duration : Period :
Allogene Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLOGENE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 7,48 $
Average target price 26,81 $
Spread / Average Target 258%
EPS Revisions
Managers and Directors
David D. Chang President, Chief Executive Officer & Director
Eric Schmidt Chief Financial Officer
Arie S. Belldegrun Executive Chairman
Alison Moore Chief Technical Officer
Barbra Sasu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ALLOGENE THERAPEUTICS, INC.-49.87%1 074
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612